Table 1.
Associations between androgen receptor (AR) expression and clinicopathological characteristics
| AR | |||
|---|---|---|---|
| Factors | Low (n=95) | High (n=155) | P-value |
| Age | |||
| ≤50 | 45 (47.4) | 63 (40.6) | 0.2981 |
| >50 | 50 (52.6) | 92 (59.4) | |
| ER positive only | |||
| ≤50 | 32 (65.3) | 57 (43.5) | 0.0088 |
| >50 | 17 (34.7) | 74 (56.5) | |
| Lymph node metastasis | |||
| Negative | 54 (56.8) | 90 (58.1) | 0.8495 |
| Positive | 41 (43.2) | 65 (41.9) | |
| Tumor size | |||
| T1 | 39 (30.5) | 80 (51.6) | 0.1376 |
| T2 | 49 (51.6) | 60 (38.7) | |
| T3 | 7 (7.4) | 15 (9.7) | |
| Nuclear grade | |||
| 1 | 29 (30.5) | 81 (52.3) | <0.0001 |
| 2 | 19 (20.0) | 40 (25.8) | |
| 3 | 47 (49.5) | 34 (21.9) | |
| ER | |||
| Negative | 46 (48.4) | 24 (15.5) | <0.0001 |
| Positive | 49 (51.6) | 131 (84.5) | |
| PR | |||
| Negative | 55 (57.9) | 59 (38.1) | 0.0022 |
| Positive | 40 (42.1) | 96 (61.9) | |
| HER2 | |||
| Negative | 69 (72.6) | 133 (85.8) | 0.0113 |
| Positive | 26 (27.4) | 22 (14.2) | |
| Subtype | |||
| HR+/HER2− | 47 (49.5) | 123 (79.4) | <0.0001 |
| HR+/HER2+ | 7 (7.4) | 12 (7.7) | |
| HER2 | 19 (20.0) | 10 (6.5) | |
| Triple negative | 22 (23.2) | 10 (6.5) | |
| Ki67 index (%) (mean±SE) | 23.7±1.5 | 14.2±1.2 | <0.0001 |
| Adjuvant therapy in ER-positive cases | |||
| None | 2 (4.1) | 13 (9.9) | 0.1413 |
| HT only | 18 (36.7) | 60 (45.8) | |
| CT only | 15 (30.6) | 22 (16.8) | |
| HT+CT | 14 (28.6) | 36 (27.5) | |
ER, estrogen receptor; PR, progesterone receptor; HT, hormone therapy; CT, chemotherapy.